Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study
Introduction: SABINA III assessed short-acting β2-agonist (SABA) prescription patterns and their association with asthma-related outcomes globally. Herein, we examined SABA prescription and clinical outcomes in the Malaysian cohort of SABINA III. Methods: In this observational, cross-sectional study...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academy of Family Physicians of Malysia
2023
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/110435/ http://psasir.upm.edu.my/id/eprint/110435/1/110435.pdf |
| _version_ | 1848867719463567360 |
|---|---|
| author | Ban, Andrea Yu-Lin Vengadasalam, Paranthaman Taher, Sri Wahyu Mohd Zim, Mohd Arif Aflah, Syazatul Syakirin Sirol Daut, Ummi Nadira Ali, Irfhan Ali Hyder Pereirasamy, Lalitha Omar, Azza Ibrahim, Aishah Mohd Tarekh, Noor Aliza Chan, Swee Kim Ali, Norsiah Mohd Isa, Nor Azila Hussain, Husni Abdul Karim, Noraziah Raja Gopal, Vieshal Chiam, Sue Yin Beekman, Maarten J. H. I. |
| author_facet | Ban, Andrea Yu-Lin Vengadasalam, Paranthaman Taher, Sri Wahyu Mohd Zim, Mohd Arif Aflah, Syazatul Syakirin Sirol Daut, Ummi Nadira Ali, Irfhan Ali Hyder Pereirasamy, Lalitha Omar, Azza Ibrahim, Aishah Mohd Tarekh, Noor Aliza Chan, Swee Kim Ali, Norsiah Mohd Isa, Nor Azila Hussain, Husni Abdul Karim, Noraziah Raja Gopal, Vieshal Chiam, Sue Yin Beekman, Maarten J. H. I. |
| author_sort | Ban, Andrea Yu-Lin |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Introduction: SABINA III assessed short-acting β2-agonist (SABA) prescription patterns and their association with asthma-related outcomes globally. Herein, we examined SABA prescription and clinical outcomes in the Malaysian cohort of SABINA III. Methods: In this observational, cross-sectional study, patients (≥12 years) were recruited between July and December 2019 from 15 primary and specialty care centres in Malaysia. Prescribed asthma treatments and severe exacerbation history within 12 months prior and asthma symptom control during the study visit were evaluated. Associations of SABA prescription with asthma control and severe exacerbation were analysed using multivariable regression models. Results: Seven hundred thirty-one patients (primary care, n=265 [36.3%]; specialty care, n=466 [63.7%]) were evaluated. The prevalence of SABA over-prescription (≥3 SABA prescriptions/year) was 47.4% (primary care, 47.1%; specialty care, 47.6%), 51.8% and 44.5% among all patients and patients with mild and moderate-to-severe asthma, respectively. Altogether 9.0% (n=66) purchased SABA without a prescription; among them, 43.9% (n=29) purchased ≥3 inhalers. The mean (standard deviation) number of severe asthma exacerbations was 1.38 (2.76), and 19.7% (n=144) and 25.7% (n=188) had uncontrolled and partly controlled symptoms, respectively. Prescriptions of ≥3 SABA inhalers (vs 1-2) were associated with lower odds of at least partly controlled asthma (odds ratio=0.42; 95% confidence interval [CI]=0.27-0.67) and higher odds of having severe exacerbation(s) (odds ratio=2.04; 95% CI=1.44-2.89). Conclusion: The prevalence of SABA over-prescription in Malaysia is high, regardless of the prescriber type, emphasising the need for healthcare providers and policymakers to adopt latest evidence-based recommendations to address this public health concern. © 2023, Academy of Family Physicians of Malaysia. All rights reserved. |
| first_indexed | 2025-11-15T14:40:58Z |
| format | Article |
| id | upm-110435 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T14:40:58Z |
| publishDate | 2023 |
| publisher | Academy of Family Physicians of Malysia |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-1104352025-09-17T08:23:23Z http://psasir.upm.edu.my/id/eprint/110435/ Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study Ban, Andrea Yu-Lin Vengadasalam, Paranthaman Taher, Sri Wahyu Mohd Zim, Mohd Arif Aflah, Syazatul Syakirin Sirol Daut, Ummi Nadira Ali, Irfhan Ali Hyder Pereirasamy, Lalitha Omar, Azza Ibrahim, Aishah Mohd Tarekh, Noor Aliza Chan, Swee Kim Ali, Norsiah Mohd Isa, Nor Azila Hussain, Husni Abdul Karim, Noraziah Raja Gopal, Vieshal Chiam, Sue Yin Beekman, Maarten J. H. I. Introduction: SABINA III assessed short-acting β2-agonist (SABA) prescription patterns and their association with asthma-related outcomes globally. Herein, we examined SABA prescription and clinical outcomes in the Malaysian cohort of SABINA III. Methods: In this observational, cross-sectional study, patients (≥12 years) were recruited between July and December 2019 from 15 primary and specialty care centres in Malaysia. Prescribed asthma treatments and severe exacerbation history within 12 months prior and asthma symptom control during the study visit were evaluated. Associations of SABA prescription with asthma control and severe exacerbation were analysed using multivariable regression models. Results: Seven hundred thirty-one patients (primary care, n=265 [36.3%]; specialty care, n=466 [63.7%]) were evaluated. The prevalence of SABA over-prescription (≥3 SABA prescriptions/year) was 47.4% (primary care, 47.1%; specialty care, 47.6%), 51.8% and 44.5% among all patients and patients with mild and moderate-to-severe asthma, respectively. Altogether 9.0% (n=66) purchased SABA without a prescription; among them, 43.9% (n=29) purchased ≥3 inhalers. The mean (standard deviation) number of severe asthma exacerbations was 1.38 (2.76), and 19.7% (n=144) and 25.7% (n=188) had uncontrolled and partly controlled symptoms, respectively. Prescriptions of ≥3 SABA inhalers (vs 1-2) were associated with lower odds of at least partly controlled asthma (odds ratio=0.42; 95% confidence interval [CI]=0.27-0.67) and higher odds of having severe exacerbation(s) (odds ratio=2.04; 95% CI=1.44-2.89). Conclusion: The prevalence of SABA over-prescription in Malaysia is high, regardless of the prescriber type, emphasising the need for healthcare providers and policymakers to adopt latest evidence-based recommendations to address this public health concern. © 2023, Academy of Family Physicians of Malaysia. All rights reserved. Academy of Family Physicians of Malysia 2023 Article PeerReviewed text en cc_by_4 http://psasir.upm.edu.my/id/eprint/110435/1/110435.pdf Ban, Andrea Yu-Lin and Vengadasalam, Paranthaman and Taher, Sri Wahyu and Mohd Zim, Mohd Arif and Aflah, Syazatul Syakirin Sirol and Daut, Ummi Nadira and Ali, Irfhan Ali Hyder and Pereirasamy, Lalitha and Omar, Azza and Ibrahim, Aishah and Mohd Tarekh, Noor Aliza and Chan, Swee Kim and Ali, Norsiah and Mohd Isa, Nor Azila and Hussain, Husni and Abdul Karim, Noraziah and Raja Gopal, Vieshal and Chiam, Sue Yin and Beekman, Maarten J. H. I. (2023) Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study. Malaysian Family Physician, 18. art. no. 32. pp. 1-17. ISSN 1985-2274 https://pmc.ncbi.nlm.nih.gov/articles/PMC10246711/pdf/MFP-18-32.pdf 10.51866/oa.258 |
| spellingShingle | Ban, Andrea Yu-Lin Vengadasalam, Paranthaman Taher, Sri Wahyu Mohd Zim, Mohd Arif Aflah, Syazatul Syakirin Sirol Daut, Ummi Nadira Ali, Irfhan Ali Hyder Pereirasamy, Lalitha Omar, Azza Ibrahim, Aishah Mohd Tarekh, Noor Aliza Chan, Swee Kim Ali, Norsiah Mohd Isa, Nor Azila Hussain, Husni Abdul Karim, Noraziah Raja Gopal, Vieshal Chiam, Sue Yin Beekman, Maarten J. H. I. Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study |
| title | Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study |
| title_full | Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study |
| title_fullStr | Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study |
| title_full_unstemmed | Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study |
| title_short | Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study |
| title_sort | short-acting β2-agonist prescription patterns and clinical outcomes in malaysia: a nationwide cohort of the sabina iii study |
| url | http://psasir.upm.edu.my/id/eprint/110435/ http://psasir.upm.edu.my/id/eprint/110435/ http://psasir.upm.edu.my/id/eprint/110435/ http://psasir.upm.edu.my/id/eprint/110435/1/110435.pdf |